Planning study for available dose of hypoxic tumor volume using fluorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer.
暂无分享,去创建一个
Seung Do Ahn | Eun Kyung Choi | Sang Hoon Jung | Ki Chun Im | Wonsik Choi | Sang-wook Lee | Sang‐wook Lee | Jong Hoon Kim | E. Choi | S. Ahn | K. Im | Sung Ho Park | J. Ryu | S. S. Kim | Jin Sook Ryu | Seung Joon Oh | S. Jung | W. Choi | S. Kim | Seung-Joon Oh
[1] P Vaupel,et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[2] Daniel A Low,et al. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. , 2003, International journal of radiation oncology, biology, physics.
[3] Chapman Jd,et al. Hypoxic sensitizers--implications for radiation therapy. , 1979 .
[4] Nathan Lawrentschuk,et al. Assessing regional hypoxia in human renal tumours using 18F‐fluoromisonidazole positron emission tomography , 2005, BJU international.
[5] M. Eble,et al. pO2 Polarography Versus Positron Emission Tomography ([18F] Fluoromisonidazole, [18F]-2-Fluoro-2’-Deoxyglucose) , 2004, Strahlentherapie und Onkologie.
[6] J. Overgaard,et al. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[7] Daniela Thorwarth,et al. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[8] M. Dewhirst,et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. , 1996, Cancer research.
[9] Sadek Nehmeh,et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. , 2008, International journal of radiation oncology, biology, physics.
[10] R Mohan,et al. Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. , 2000, International journal of radiation oncology, biology, physics.
[11] T W Griffin,et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. , 1992, International journal of radiation oncology, biology, physics.
[12] M. Piert,et al. Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia , 1999, European Journal of Nuclear Medicine.
[13] K. Krohn,et al. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. , 1989, International journal of radiation oncology, biology, physics.
[14] Martin Westhofen,et al. FDG—a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[15] David L. Schwartz,et al. Tumor Hypoxia Imaging with [F-18] Fluoromisonidazole Positron Emission Tomography in Head and Neck Cancer , 2006, Clinical Cancer Research.
[16] D. Mankoff,et al. Hypoxia imaging-directed radiation treatment planning , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[17] Sang‐wook Lee,et al. Preliminary results of a phase I/II study of simultaneous modulated accelerated radiotherapy for nondisseminated nasopharyngeal carcinoma. , 2006, International journal of radiation oncology, biology, physics.
[18] X Allen Li,et al. Simultaneous integrated boost for breast cancer using IMRT: a radiobiological and treatment planning study. , 2004, International journal of radiation oncology, biology, physics.
[19] Radhe Mohan,et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results. , 2004, International journal of radiation oncology, biology, physics.
[20] M. Dewhirst,et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.
[21] T. Pickles,et al. Impact of nicotinamide on human tumour hypoxic fraction measured using the comet assay. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[22] M. Piert,et al. Dependency of the [18F]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. , 2000, Nuclear medicine and biology.
[23] S Mutic,et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. , 2001, International journal of radiation oncology, biology, physics.
[24] J. Deasy,et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. , 2001, International journal of radiation oncology, biology, physics.
[25] Jens Overgaard,et al. Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer , 2004, Acta oncologica.
[26] Matthias Reimold,et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] M. Graham,et al. Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] P. Olive,et al. Heterogeneity in human tumour hypoxic fraction using the comet assay. , 1996, The British journal of cancer. Supplement.
[29] D. Brizel,et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[30] Lester J. Peters,et al. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[31] R. Fisher,et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] I. Olivotto,et al. Gel electrophoresis of individual cells to quantify hypoxic fraction in human breast cancers. , 1993, Cancer research.
[33] P. Xia,et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. , 2001, International journal of radiation oncology, biology, physics.
[34] Heinz H. Coenen,et al. pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. , 2004 .
[35] Richard A Popple,et al. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. , 2002, International journal of radiation oncology, biology, physics.